drugset

drugset / Trial / NCT06222294

A Study of Remimazolam Tosilate for Sedation in the ICU

NCT06222294 ↗

Phase 3 Completed 214 enrolled Jiangsu HengRui Medicine Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in the ICU.

Timeline

Start: 2024-03-12
Primary completion: 2024-08-13
Completion: 2024-09-24

Publications

Guan X, Liu N, Lin F, Yu J, Yang M, Zhou Q, Chen K, Yu X, Huang X, Zhu J, Lyu J, Gui C, Hu Z, Zheng S, He B, Wang M, Yu Z, Ma X, Lv A, Zhang J, Xu J, Ye J, Gong J, Tian X, Zhou J, Zhou F, Yu L, He W, Li X, Yin T, Zhao H, Ding Y, Chen M. Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: A Multicenter, Randomized, Single-blind, Noninferiority, Phase 3 Trial. Anesthesiology. 2026 Jul 1;145(1):72-83. doi: 10.1097/ALN.0000000000006047. Epub 2026 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Propofol	Small molecule	0.3 mg/kg	Intravenous
Comparator	Propofol	Small molecule	4 mg/kg	Intravenous
Subject	Remimazolam	Small molecule	0 mg/kg	Intravenous
Subject	Remimazolam	Small molecule	2 mg/kg	Intravenous

Indications

No indication recorded.